Approval belongs to a specific product
An FDA-approved medicine has been reviewed for its labeled uses, manufacturing quality, safety and effectiveness. Compounded drugs are not FDA-approved. A familiar active-ingredient name on a provider page does not transfer approval from Wegovy, Zepbound or another approved product to the compounded preparation being sold.
Sources: FDA — compounding questions and answers, FDA — concerns with unapproved GLP-1 drugs, Wegovy — prescribing information, Zepbound — prescribing information
A prescription does not answer every question
Compounding can serve a patient whose medical needs cannot be met by an approved product, subject to applicable conditions. Whether a particular preparation may lawfully be compounded depends on the facts and current requirements. A provider’s willingness to sell a program is not, by itself, proof that the preparation meets every condition or is appropriate for an individual patient.
Sources: FDA — compounding questions and answers, FDA — concerns with unapproved GLP-1 drugs, Wegovy — prescribing information, Zepbound — prescribing information
FDA identifies specific GLP-1 concerns
The agency’s information on unapproved GLP-1 drugs discusses dosing errors, adverse events, misleading online sales and use of salt forms. Different concentrations and instructions can contribute to mistakes. The useful response is to verify the actual preparation, dispensing pharmacy, concentration, labeling and clinician instructions, rather than assuming every vial is a interchangeable version of a familiar brand.
Sources: FDA — compounding questions and answers, FDA — concerns with unapproved GLP-1 drugs, Wegovy — prescribing information, Zepbound — prescribing information
How this changes the comparison
Our boards mark each offer by its stated product status and route. We do not award a safety score based on a price page, call a compounded product an approved generic, or recommend changing medication to save money. A clinician and pharmacist should resolve treatment and dispensing questions. The comparison is designed to make commercial terms easier to inspect after those questions are addressed.
Sources: FDA — compounding questions and answers, FDA — concerns with unapproved GLP-1 drugs, Wegovy — prescribing information, Zepbound — prescribing information
Follow the evidence
Sources & price notes
Checked October 8, 2026. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- FDA — compounding questions and answers ↗
Clinical and regulatory context. A compounded preparation is not FDA-approved.
- FDA — concerns with unapproved GLP-1 drugs ↗
Safety, dosing errors, salt forms and misleading online marketing.
- Wegovy — prescribing information ↗
Formulation-specific approved uses, contraindications and warnings.
- Zepbound — prescribing information ↗
Approved uses, contraindications and warnings.